Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart disease and stroke statistics–2012 update: a report from the American Heart Association.Circulation. 2012; 125: e2-e220
- Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond.Circulation. 2010; 121: 586-613
- Robbins and Cotran pathologic basis of disease.8th edition. Saunders Elsevier, Philadelphia2010
- Atherosclerosis–an inflammatory disease.N Engl J Med. 1999; 340: 115-126
- Lipids, lipoproteins, and cardiovascular risk.in: Lewandrowski K. Clinical chemistry: laboratory management and clinical correlations. Lippincott Williams & Wilkins, Philadelphia2002: 575-591
- Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing.Clin Chem Lab Med. 2012; 50: 1169-1181
- Clinical practice. Low HDL cholesterol levels.N Engl J Med. 2005; 353: 1252-1260
- Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation. 2002; 106: 3143-3421
- Increasing HDL cholesterol levels.N Engl J Med. 2004; 350: 1491-1494
- HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.N Engl J Med. 2007; 357: 1301-1310
- Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy.Clin Chem Lab Med. 2007; 45: 1319-1325
- PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol.Clin Chem Lab Med. 2008; 46: 490-498
- The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease.Clin Chem Lab Med. 2006; 44: 1015-1021
- Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.CMAJ. 2003; 169: 921-924
- 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.Can J Cardiol. 2013; 29: 151-167
- Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?.Clin Chem. 2013; 59: 723-725
- Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.Clin Chem. 2013; 59: 752-770
- Biomarkers and cardiovascular risk assessment for primary prevention: an update.Clin Chem. 2012; 58: 72-82
- Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?.Clin Chem Lab Med. 2009; 47: 128-137
- Benchmarks for the assessment of novel cardiovascular biomarkers.Circulation. 2007; 115: 949-952
- C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction.Clin Chem. 2011; 57: 1757-1761
- The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.Clin Chem. 2009; 55: 219-228
- Clinical utility of lipoprotein-associated phospholipase A(2) for cardiovascular disease prediction in a multiethnic cohort of women.Clin Chem. 2012; 58: 1352-1363
- Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment.Clin Chem. 2003; 49: 1258-1271
- C-reactive protein levels and outcomes after statin therapy.N Engl J Med. 2005; 352: 20-28
- Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)–can C-reactive protein be used to target statin therapy in primary prevention?.Am J Cardiol. 2006; 97: 33A-41A
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008; 359: 2195-2207
- Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.Clin Chem Lab Med. 2010; 48: 1685-1691
- Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.N Engl J Med. 2002; 347: 1557-1565
- High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?.J Am Coll Cardiol. 2013; 62: 397-408
- Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors.Clin Chem. 2009; 55: 322-335
- Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.Mayo Clin Proc. 2007; 82: 159-165
- Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.Clin Chem Lab Med. 2012; 50: 1825-1831
- Lipoprotein-associated phospholipase A(2) measurements: mass, activity, but little productivity.Clin Chem. 2012; 58: 814-817
- Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Lancet. 2010; 375: 1536-1544
- Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.Chem Res Toxicol. 2010; 23: 447-454
- Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein.Ann Clin Lab Sci. 2012; 42: 384-391
- Lipoprotein(a) as a cardiovascular risk factor: current status.Eur Heart J. 2010; 31: 2844-2853
- Lipoprotein(a): resurrected by genetics.J Intern Med. 2013; 273: 6-30
- Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.JAMA. 2009; 302: 412-423
- Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med. 2011; 365: 2255-2267
- Genomewide association studies in cardiovascular disease–an update 2011.Clin Chem. 2012; 58: 92-103
- Genomewide association analysis of coronary artery disease.N Engl J Med. 2007; 357: 443-453
- Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease.Atherosclerosis. 2010; 208: 183-189
- Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada.Atherosclerosis. 2009; 203: 192-200
- Association of high sensitive C-reactive protein with apolipoprotein E polymorphism in children and young adults: the Cardiovascular Risk in Young Finns Study.Clin Chem Lab Med. 2008; 46: 179-186
- ApoE genotype as risk factor in dialysis patients.Atherosclerosis. 2010; 212 ([author reply: 697]): 695-696
- Genetic variants associated with Lp(a) lipoprotein level and coronary disease.N Engl J Med. 2009; 361: 2518-2528
- Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.Curr Atheroscler Rep. 2013; 15: 310
- Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.N Engl J Med. 2012; 366: 1108-1118
Article info
Publication history
Published online: January 16, 2014
Footnotes
The authors have no conflicts of interest.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
